Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003102 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00003102 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 15 participants.
The verdict
NCT00003102, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.
Interventions
- BIOLOGICAL Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1998-11-17 |
| Est. Completion | 2003-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003102
The ClinicalTrials.gov registry entry for NCT00003102 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250) is the first listed.
NCT00003102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003102 about?
NCT00003102 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.
What is the current status of trial NCT00003102?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1998-11-17. Estimated completion is 2003-05-27.
What interventions are being tested in trial NCT00003102?
The interventions under investigation include: Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003102?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.